Patient characteristics according to DNMT3Amut status
| . | No. (%) . | P . | |
|---|---|---|---|
| DNMT3AWT (n = 85) . | DNMT3Amut (n = 79) . | ||
| Female sex | 51 (60) | 36 (46) | .08 |
| Age, y | .7 | ||
| Median | 53 | 53 | |
| Range | 18-71 | 25-72 | |
| WBC, × 109/L | <.001 | ||
| Median | 16 | 50 | |
| Range | 0.55-408 | 1.3-384 | |
| BM blasts, % | .7 | ||
| Median | 73 | 73 | |
| Range | 20-100 | 20-100 | |
| Platelet count, × 109/L | .4 | ||
| Median | 64 | 70 | |
| Range | 8-488 | 12-625 | |
| FLT3 mutational status | .6 | ||
| WT | 46 (54) | 40 (50) | |
| FLT3low | 19 (22) | 15 (19) | |
| FLT3high | 19 (22) | 23 (30) | |
| Treatment protocol | |||
| AML-03 | 26 (31) | 22 (28) | |
| AML-12 | 59 (69) | 57 (72) | |
| Postinduction CR | 75 (88) | 69 (87) | .7 |
| No. of cycles to achieve CR (1 vs 2) | 67 vs 8 | 61 vs 8 | .86 |
| No. of patients undergoing alloHSCT in CR1 | 16 (19) | 22 (28) | .9 |
| . | No. (%) . | P . | |
|---|---|---|---|
| DNMT3AWT (n = 85) . | DNMT3Amut (n = 79) . | ||
| Female sex | 51 (60) | 36 (46) | .08 |
| Age, y | .7 | ||
| Median | 53 | 53 | |
| Range | 18-71 | 25-72 | |
| WBC, × 109/L | <.001 | ||
| Median | 16 | 50 | |
| Range | 0.55-408 | 1.3-384 | |
| BM blasts, % | .7 | ||
| Median | 73 | 73 | |
| Range | 20-100 | 20-100 | |
| Platelet count, × 109/L | .4 | ||
| Median | 64 | 70 | |
| Range | 8-488 | 12-625 | |
| FLT3 mutational status | .6 | ||
| WT | 46 (54) | 40 (50) | |
| FLT3low | 19 (22) | 15 (19) | |
| FLT3high | 19 (22) | 23 (30) | |
| Treatment protocol | |||
| AML-03 | 26 (31) | 22 (28) | |
| AML-12 | 59 (69) | 57 (72) | |
| Postinduction CR | 75 (88) | 69 (87) | .7 |
| No. of cycles to achieve CR (1 vs 2) | 67 vs 8 | 61 vs 8 | .86 |
| No. of patients undergoing alloHSCT in CR1 | 16 (19) | 22 (28) | .9 |
BM, bone marrow.